Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced a collaboration agreement with the
Karolinska Institutet for research applications and product
development utilizing CyTOF® XT, the fourth-generation platform
based on Fluidigm’s pioneering CyTOF technology.
The Karolinska Institutet, based in Stockholm, is one of the
world’s foremost medical universities and Sweden’s largest single
center of academic medical research. The collaboration will focus
on CyTOF based research performed in the Institute’s Department of
Women’s and Children’s Health.
“Research in the Institute’s Department of Women’s and
Children’s Health focuses on cellular interactions governing
immune system behavior in health and disease and human immune
system variation, as well as immune development in children,” said
Petter Brodin, MD, PhD, Professor of Immunology. “We are building a
body of knowledge about the immune system, particularly in early
childhood development, that we believe will have broad implications
in future health care decision making. CyTOF provides detailed data
that can shed light on immunological makeup and responses, leading
to development of therapies that are most effective for
patients.
“Mass cytometry has enabled Karolinska Institutet to conduct
significant immunological research in recent years that has yielded
insights that inform new therapies. We acquired a CyTOF XT to
expand our capabilities in this regard, providing rich data to help
us better understand the incredibly complex human immune system,
with advancements in throughput, automation and time to results,”
said Brodin.
CyTOF XT™, launched in mid-2021, is designed to simplify the
design and execution of deep cell profiling studies, standardize
sample analysis with reproducible workflows and automation and
accelerate novel therapeutic development research to improve human
health. The features of CyTOF XT are particularly valuable to
translational and clinical researchers across the pharmaceutical
and biotechnology sectors and the contract research organizations
that serve them.
“Collaborating with one of the world’s most prestigious medical
universities is an honor for Fluidigm, and we are excited to
partner with Karolinska Institutet,” said Chris Linthwaite,
Fluidigm President and CEO. “This collaboration underscores the
acceleration of CyTOF as a premier tool for translational and
clinical research and its role in developing a more meaningful
approach to precision medicine for better health care decision
making.
“The new CyTOF XT platform provides the most reliable and
reproducible method to capture the complexity of the human immune
system through high-dimensional cytometry, with improvements in
throughput, automation and time to results as well as total cost of
ownership.”
As part of the collaboration, the Karolinska Institutet will
receive early access to reagents and software under development by
Fluidigm, evaluate pre-released Fluidigm® materials and products
under development, participate in Fluidigm events and host visits
or experiments by Fluidigm customers or prospects relating to
Helios™, a CyTOF system, and CyTOF XT, and participate in product
development discussions with respect to Helios and CyTOF XT.
Among key growth strategies for Fluidigm is driving adoption of
the technology in translational and clinical research, as well as
accelerating consumables and assay development through increased
organic investment and partnership. Globally, mass cytometry is
utilized by 9 of the top 10 pharma companies. Mass cytometry
technologies, including CyTOF, Imaging Mass Cytometry™ (IMC™) and
Maxpar® Direct™, have been used in more than 160 National
Clinical Trials.
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
For Research Use Only. Not for use in diagnostic
procedures.Information in this publication is subject to
change without notice. Limited Use License:
fluidigm.com/legal/salesterms; Patents: fluidigm.com/legal/notices.
Trademarks: Fluidigm, the Fluidigm logo, CyTOF, CyTOF XT, Direct,
Helios, Imaging Mass Cytometry, IMC and Maxpar are trademarks
and/or registered trademarks of Fluidigm Corporation or its
subsidiaries in the United States and/or other countries. © 2021
Fluidigm Corporation. All rights reserved. 09/2021
Forward-Looking Statements for Fluidigm This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the potential
benefits of research conducted using Fluidigm technology and
products and anticipated benefits to Fluidigm of a collaboration,
including Fluidigm product development and growth. Forward-looking
statements are subject to numerous risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including but not limited to risks relating to
challenges inherent in developing, manufacturing, launching,
marketing, and selling new products; potential product performance
and quality issues; intellectual property risks; competition;
uncertainties in contractual relationships; and reductions in
research and development spending or changes in budget priorities
by customers. Information on these and additional risks and
uncertainties and other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2020, and in its other filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Fluidigm disclaims any
obligation to update these forward-looking statements except as may
be required by law.
Available InformationWe use our
website (fluidigm.com), investor site
(investors.fluidigm.com), corporate Twitter account (@fluidigm),
Facebook page (facebook.com/Fluidigm), and LinkedIn page
(linkedin.com/company/fluidigm-corporation) as channels of
distribution of information about our products, our planned
financial and other announcements, our attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and webcasts.
About The Karolinska Institutet Karolinska
Institutet is one of the world’s leading medical universities. Our
vision is to advance knowledge about life and strive towards better
health for all. The Karolinska Institutet accounts for the single
largest share of all academic medical research conducted in Sweden
and offers the country’s broadest range of education in medicine
and health sciences. The Nobel Assembly at Karolinska Institutet
selects the Nobel laureates in Physiology or Medicine.
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Investors:Peter DeNardo415 389
6400ir@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024